Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health

Similar documents
2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5

First Name. Specialty: Fax. First Name DOB: Duration:

PedsCases Podcast Scripts

Clinical Guideline POSITION STATEMENT ON THE INVESTIGATION AND TREATMENT OF GROWTH HORMONE DEFICIENCY IN TRANSITION

GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT

Growth and Puberty: A clinical approach. Dr Esko Wiltshire

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

Growth Hormones DRUG.00009

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

Why is my body not changing? Conflicts of interest. Overview 11/9/2015. None

4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!

R ecombinant growth hormone (GH) treatment is recommended

Request for Prior Authorization Growth Hormone (Norditropin

CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

PHARMACY POLICY STATEMENT Indiana Medicaid

PHARMACY POLICY STATEMENT Indiana Medicaid

Clinical Standards for GH Treatment in Childhood & Adolescence.

Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,

Endocrine system overview

General Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)

Endocrine Quiz / overview. Endocrine Quiz. Pituitary insufficiency. Genetic causes of hypopituitarism. Acquired MPHD Order of hormone loss..

Original Effective Date: 7/5/2007

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka

Birth weight influences long-term catch-up growth and height prognosis of GH-deficient children treated before the age of 2 years

Original Article Pituitary imaging in 129 children with growth hormone deficiency: A spectrum of findings

Endocrine part two. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy

Endocrine part one. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy

Checking the Right Box at the Right Age: the Art of Pediatric Endocrine Testing

Aetna Better Health of Virginia

Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia

Growth Hormone!gents. WA.PHAR.50 Growth Hormone Agents

Pharmacy Prior Authorization Growth Hormone- Clinical Guidelines

Somatostatin Analog and Estrogen Treatment in a Tall Girl

Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit

GROWTH: A Clinical Perspective. Sharon E. Oberfield, M.D. Professor of Pediatrics Columbia University Medical Center February 12, 2007

How to approach a child with growth concern

GROWTH: A Clinical Perspective. Sharon E. Oberfield, M.D. Professor of Pediatrics Columbia University Medical Center February 12, 2007

PITUITARY: JUST THE BASICS PART 2 THE PATIENT

GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK

The science behind igro

Idiopathic central precocious puberty associated with an enlarged pituitary gland

What we will cover. Evaluation of the Child with Suspected Pituitary Disease. ituitary

Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Endocrinological Outcome Among Treated Craniopharyngioma Patients

Puberty and Pubertal Disorders Part 3: Delayed Puberty

BIOM2010 (till mid sem) Endocrinology. e.g. anterior pituitary gland, thyroid, adrenal. Pineal Heart GI Female

Evaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS

GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY ADULT

Growth Hormone Therapy

Growth IGF Analyte Information

Dr. Nermine Salah El-Din Prof of Pediatrics

Chapter 7: Endocrine Disorders

AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents

Growth Hormone, Somatostatin, and Prolactin 1 & 2 Mohammed Y. Kalimi, Ph.D.

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

Cigna Drug and Biologic Coverage Policy

Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany

2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

DR. SHAHJADA SELIM. Growth Hormone Deficiency. Subdivisions of Growth Hormone Deficiency. General Discussion. Signs & Symptoms

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

OBJECTIVES. Rebecca McEachern, MD. Puberty: Too early, Too Late or Just Right? Special Acknowledgements. Maryann Johnson M.Ed.

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

Laboratory Investigation of Male Gonadal Function. Dr N Oosthuizen Dept of Chemical Pathology UP 2010

PENS 2017 Minneapolis, MN April 27, Disclosure. Objectives: Growth Hormone Guidelines Roundtable

Reproductive Health and Pituitary Disease

PedsCases Podcast Scripts

Pituitary Stalk Interruption Syndrome. Leena Shahla, MD, PGY5 Endocrinology, Diabetes and Metabolism Fellowship University of Massachusetts

High and Low GH: an update of diagnosis and management of GH disorders

Audit of Adrenal Function Tests. Kate Davies Senior Lecturer in Children s Nursing London South Bank University London, UK

TRANSITIONING FROM A PEDIATRIC TO AN ADULT ENDOCRINOLOGIST CARLOS A. LEYVA JORDÁN, M.D. PEDIATRIC ENDOCRINOLOGIST

3 year old boy with puberty. Katie Stanley, MD August 1, 2013

GROWTH HORMONE THERAPY

Loss of function mutations in IGSF1 cause an X linked syndrome of central hypothyroidism and testicular enlargement.

Growth Hormone Deficiency: Diagnostic Principles and Practice

DISCLAIMER SUMMARY OF EVIDENCE/POSITION

IT IS WIDELY recognized that the diagnosis of GH deficiency

Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure

Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea

STRANGE THYROID FUNCTION TESTS: REAL PATHOLOGY OR BIOLOGICAL PITFALL? Agnès Burniat, MD, PhD

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Disorders of Growth and Development: Diagnosis and Treatment

UW MEDICINE PATIENT EDUCATION. Acromegaly Symptoms and treatments. What is acromegaly? DRAFT. What are the symptoms? How is it diagnosed?

Original Effective Date: 7/5/2007

Original article Central Eur J Paed 2018;14(1):68-72 DOI /p

GROWTH HORMONE THERAPY

A Boy without Growth Hormone is Growing Normally

Growth Hormone: Review of the Evidence

Peri-op Pituitary / Diabetes Insipidus/ Apoplexy Dr. Stan Van Uum, MD, PhD, FRCPC

Elements for a Public Summary

GROWTH HORMONE THERAPY

Effective September 30, 2011 Please refer to the Pharmacy policy for the new coverage criteria

Pharmacy Management Drug Policy

Humatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen

Transcription:

Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health

Content Normal pattern of growth and its variation Using growth charts Interpreting auxological measures Recognising an abnormal growth pattern Clues in the history Triggers to the decision to undertake investigation Types of investigation Making a diagnosis

Anthropometry GH + sex steroid dependent Nutrition dependent phase GH dependent GV >5 cm/yr GV >8 cm/yr Parental target range Height Age

Plotting Growth Data Mid-parental height from Mother s & Father s heights Parental target Target height in relation to parental heights (cms) Boys FH + MH + 7 2 Girls FH + MH - 7 2 4

Pubertal Staging: A. Genital & Pubic Hair development in Boys B. Pubic Hair development in Girls C. Breast development in Girls 5

Bone Age If delayed compared to chronological age suggestive of chronic underlying problem, but not necessarily endocrine. Normal BA = CA +/- 1 year 6

Growth & Puberty are inextricably linked Mid-parental height from Mother s & Father s heights + details on parental, sibling puberty 7

Process to Follow: History Medical clues System screen Impact on life Internet exploration* Physical Examination System screen Growth & puberty assessment Explore expectations* Formulate a differential diagnosis [Order tests] [Evaluate tests] Reach a diagnosis or reformulate differential diagnosis 8

Causes of Short Stature: Idiopathic short stature, including Constitutional delay of growth & puberty Genetic / Familial SS Associated with systemic disease Born small with failure of catch-up Chromosomal / Genetic syndrome [monogenic] Psychosocial Endocrine Bone dysplasia [Primary malnutrition] Three specific growth therapies: r-hgh r-higf-i Sex steroids GH Deficiency / Hypopituitarism Primary Secondary Hypothyroidism

GH + sex steroid dependent Nutrition dependent phase GH dependent GV >5 cm/yr GV >8 cm/yr Parental target range Causes: Causes: Chronic disease GHD Height Syndromes eg Turners, Skeletal dysplasia Psychosocial Endocrine Causes: SGA Sex steroid deficiency If GHD, then exclude SOL urgently Age

Skeletal dysplasias Achondroplasia Causes: Height Chronic disease Syndromes eg Turners, Skeletal dysplasia Psychosocial SGA Age

Russell Silver Syndrome Causes: Chronic disease Height Syndromes eg Turners, Skeletal dysplasia Psychosocial SGA SGA Tendency toward hypoglycaemia Methylation abnormaities on Chr 11 UPD maternal Chr 7

Hypothyroidism

Coeliac disease

Psycho-social deprivation

Screening Investigations in a Short child: System disorder, Endocrine Hormone Subject Normal range (15yr old male) Free T4 (Thyroxine) 18 pmol/l 9-24 pmol/l TSH (Thyroid Stimulating Hormone) 2.1 mu/l 0.3-3.0 mu/l IGF-I (Insulin-like growth factor 1) 110 µg/l 168-859 µg/l 19

Concentrations of IGF-I in blood versus Age X X Juul et al JCEM 1994 20

Identifying GH Deficiency: History, phenotype & anthropometry Defining the status of the GH-IGF axis MR imaging with specific views of the hypothalamic-pituitary axis Genetic analysis Infant : Early - Late Childhood : Teens

Neonatal Tips in the History Hypoglycaemia, prolonged jaundice, microphallus, traumatic delivery Prior pituitary insult Cranial irradiation Tumour, infiltration, infection Trauma Family history Consanguinity Persistent decrease in growth rate

Case1 Term Female with Hypoglycaemia & prolonged jaundice Basal TFT TSH 9.5u/L, ft 4 9pmol/L TRH TSH 9-20-22u/L LDST Cortisol Peak 300nmol/L GH stimulation Peak GH 15µg/L IGF-I sds -4 Treatment started with T 4, Hydrocortisone & GH MRI Small Ant Pit, Ectopic PP, Stalk visible, midline intact Diagnosis: Congenital Hypopituitarism Age 6-8 weeks Not fixing consistently, eye wobble noted. Ophthalmic review Small Optic Discs

Phenotype: GH Deficiency

Isolated, idiopathic GHD ± MR hypothalamic-pituitary abnormalities

26

The venue, refreshments and speakers have been funded by

Anthropometry

Hypothalamus Pituitary GHRH Defining the GH- IGF axis Status GH GH Receptor GH Cell-associated IGFBP/ IGF complex Liver IGF-I ALS IGFBP-3 IGF-I Receptor Ternary complex Target Tissues e.g.bone, muscle IGFBP / IGF complexes IGF-I

GH Tests Insulin Tolerance Test Arginine Glucagon Clonidine Sleep GHRH + Arginine Profiles 12hr, 24hr, overnight Urinary GH Normative data Assay issues Priming Cut-off levels

GH maximal response, under placebo (P) or E2 administration in SS and GHD children. MartÍnez A S et al. JCEM 2000;85:4168-4172 2000 by Endocrine Society

GH Assay Issues Cut-off Levels in GH Stimulation Tests Wagner et al EJE 2014

GH Cut-off Levels <3 µg/l <5 <6.1 <6.7 <7 <10 Severe childhood GHD: Adult GHD cut-off Transition GHD cut-off Transition GHD cut-off Childhood GHD cut-off [monoclonal assays] Childhood GHD cut-off Childhood GHD cut-off [older polyclonal assays]

Normative Data for serum IGF-I and IGFBP-3 IGF-I levels in Males from Juul et al JCEM 1994 IGFBP-3 levels in Males from Juul et al JCEM 1995

An example of performance of serum IGF-I and IGFBP-3 assessments Ranke et al Horm Res 2000

Cut-off Values (using ROCs) for IGF-I and IGFBP-3 SDS in the diagnosis of GHD, defined by peak GH level <7µg/L Sensitivity 68% Specificity 97% Sens 60% Spec 90% Boquete et al JCEM 2003

The Process (Personal Practice) Once a decision is made to undertake GH provocation testing, then other pituitary function needs to be checked Single Provocation test (1st choice agent: Arginine) & serum IGF-I If there is a test failure (peak GH < cut-off) & background clinical risk factor / recognised associated condition, then accept as GHD, and ensure hp axis MR done If there is a test failure with no risk factors, second Provocation test (2nd choice agent: Glucagon) & repeat serum IGF-I If both GH tests failed, arrange hp axis MR

Leger et al JCEM 2005

We know when we have genuine GHD, but significant uncertainty remains when we have biochemical GHD without MR abnormality, or only minor anomaly

Genetics

Case 2 First seen at 2 years with poor growth from birth Normal developmental milestones Positive history of short stature in paternal grandfather By the age of 7 years, she was self-conscious, manipulative and was showing deterioration in her school performance Mid-parental height 25 th centile Initial Investigations: FBC, ECG, Blood sugar, Urinalysis, Urea & Electrolyte, Chest radiograph Normal

Case 2 Marked short stature Cause not defined Differential diagnosis: Skeletal dysplasia Storage Disorder (Mucopolysaccharidosis) GH deficiency Further investigations required for which facilities were not available in Nigeria Age 7 years

Summary of Pituitary Investigations in the UK Test Result Comment Arginine Stimulation test - peak GH <0.05mcg/l low level IGF-1 33ng/ml low Prolactin <50mu/l low Synacthen Test Cortisol (nmol/l) Basal 30 minute 60 minute GnRH Test Basal 30 minute 60 minute TRH test Basal TSH 15minute TSH 60minute TSH Free T4 161 667 881 LH (U/l) FSH (U/l) <0.1 1.1 1.7 10 2.6 14 3.4mu/l 3.6mu/l 3.3mu/l 9pmol/l Normal result Normal result normal normal low What is the Diagnosis?

PIT1/R271W mutation in exon 6 Heterozygous c>t change indicated by circle (cgg>tgg, R>W) Dominant mutation in POU1F1 Turton, J. P. G. et al. J Clin Endocrinol Metab 2005;90:4762-4770

rhgh & T4

Guiding Clinical Practice Clinicians should be familiar with the details of the assays used in their local laboratories for GH, IGF-I and IGFBP-3. Where local GH assay and test specific data on cut-offs for stimulation tests are not available, we would recommend the use of cut-off values described by Wagner et al. Normative data are available for most IGF-I and IGFBP-3 assays. These should be used when interpreting results. The diagnosis of GHD remains multifactorial and our practice is based around Consensus Guidelines. MR imaging should include specific views of the hypothalamic-pituitary axis. Our practice is to prime all prepubertal patients (aged >8 years for girls or >9 years for boys) prior to GH stimulation testing; oral oestrogen based preparations are used for girls and boys. Genetic tests may be required to confirm diagnoses

Conclusions Regular plotting of growth data on an appropriate chart Recognising an abnormal growth pattern & triggering investigations Hierarchical approach Achieving a specific diagnosis